Wave Life Sciences Ltd. - Ordinary Shares (WVE) News

Wave Life Sciences Ltd. - Ordinary Shares (WVE): $5.11

0.18 (+3.65%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

Filter WVE News Items

WVE News Results

Date Symbol Company Title Start End Change POWR Rating
Loading, please wait...

WVE News Highlights

  • WVE's 30 day story count now stands at 5.
  • Over the past 22 days, the trend for WVE's stories per day has been choppy and unclear. It has oscillated between 1 and 2.
  • The most mentioned tickers in articles about WVE are WAVE, ROSE and BIO.

Latest WVE News From Around the Web

Below are the latest news stories about WAVE LIFE SCIENCES LTD that investors may wish to consider to help them evaluate WVE as an investment opportunity.

Wave Life Sciences (NASDAQ:WVE) shareholders have earned a 115% return over the last year

It certainly might concern Wave Life Sciences Ltd. ( NASDAQ:WVE ) shareholders to see the share price down 30% in just...

Yahoo | January 25, 2023

Wave Life Sciences Ltd. (NASDAQ:WVE) Stock Could Be Worth Considering

Wave Life Sciences Ltd. (NASDAQ:WVE) price on Friday, January 13, rose 4.00% above its previous day’s close as an upside momentum from buyers pushed the stock’s value to $5.46. A look at the stock’s price movement, the close in the last trading session was $5.25, moving within a range at $5.13 and $5.695. The beta … Wave Life Sciences Ltd. (NASDAQ:WVE) Stock Could Be Worth Considering Read More »

Stocks Register | January 14, 2023

How should investors view Wave Life Sciences Ltd. (WVE)?

Wave Life Sciences Ltd. (NASDAQ:WVE) marked $5.25 per share on Thursday, down from a previous closing price of $5.26. While Wave Life Sciences Ltd. has underperformed by -0.19%, investors are advised to look at stock chart patterns for technical insight. Within its last year performance, WVE rose by 93.73%, with highs and lows ranging from […]

US Post News | January 13, 2023

Morphic Holding, Inc. (MORF) Surges 18.7%: Is This an Indication of Further Gains?

Morphic Holding, Inc. (MORF) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.

Yahoo | January 13, 2023

The Zacks Analyst Blog Highlights AVEO Pharmaceuticals, Cabaletta Bio, Verona Pharma and Wave Life Sciences

AVEO Pharmaceuticals, Cabaletta Bio, Verona Pharma and Wave Life Sciences are included in this Analyst Blog.

Yahoo | January 3, 2023

All You Need to Know About Wave Life Sciences (WVE) Rating Upgrade to Buy

Wave Life Sciences (WVE) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

Yahoo | December 30, 2022

4 Drug Stocks That More Than Doubled This Year

We present four biotech stocks, AVEO, CABA, VRNA and WVE, which despite the current volatile market, have provided more than twice the returns in 2022.

Yahoo | December 30, 2022

Wave Life Sciences Provides Positive Update on Proof-of-Concept Study for WVE-N531 in Duchenne Muscular Dystrophy

53% mean exon skipping and <1% (BLQ) mean dystrophin expression six weeks after initiating biweekly multidosing

GlobeNewswire | December 19, 2022

Wave Life Sciences Touts Encouraging Data From Duchenne Muscular Dystrophy Study

Wave Life Sciences Ltd (NASDAQ: WVE) announced an update from the initial cohort of the Phase 1b/2a proof-of-concept study of WVE-N531 in three boys with Duchenne muscular dystrophy (DMD) amenable to exon 53 skipping. High muscle concentrations of WVE-N531 and exon skipping were observed six weeks after initiating biweekly multi-dosing at 10 mg/kg, achieving proof-of-concept in the study. Related: Wave Life Sciences Shares Move Higher On Therapeutic Pact With GSK Targeting Genetic Disorders. WVE

Yahoo | December 19, 2022

Wave Life Sciences (WVE) Up 26% on Collaboration With GSK

Wave Lifesciences (WVE) signs a four-year research collaboration with GSK to advance discovery and development of oligonucleotide therapeutics focusing on novel genetic targets

Yahoo | December 15, 2022


Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!




Page generated in 0.521 seconds.